Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors
A Pilot, Non-Therapeutic NeuroImaging Study of 18F-FLT in Pediatric Patients With Newly Diagnosed Central Nervous System Tumors
Status: Enrolling
Updated:  4/5/2018
Children's Hospital Boston
mi
from
Boston, MA
A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors
A Pilot, Non-Therapeutic NeuroImaging Study of 18F-FLT in Pediatric Patients With Newly Diagnosed Central Nervous System Tumors
Status: Enrolling
Updated: 4/5/2018
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  4/5/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 4/5/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  4/5/2018
Washington University
mi
from
Saint Louis, MO
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 4/5/2018
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  4/5/2018
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 4/5/2018
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  4/5/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 4/5/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Duke Univ Med Ctr
mi
from
Durham, NC
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Texas Children'S Cancer Center
mi
from
Houston, TX
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Texas Children'S Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Lucile Packard Children's Hospital at Stanford University Medical Center
mi
from
Palo Alto, CA
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Lucile Packard Children's Hospital at Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Children's Hospital Boston
mi
from
Boston, MA
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Cook Children's Medical Center - Fort Worth
mi
from
Fort Worth, TX
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Cook Children's Medical Center - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated:  4/9/2018
Hospital for Sick Children
mi
from
Toronto,
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma
Status: Enrolling
Updated: 4/9/2018
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated:  4/11/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated: 4/11/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated:  4/11/2018
Columbia University Medical Center
mi
from
New York, NY
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated: 4/11/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated:  4/11/2018
University of Virginia
mi
from
Charlottesville, VA
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated: 4/11/2018
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated:  4/11/2018
Northwestern University
mi
from
Chicago, IL
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated: 4/11/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated:  4/11/2018
Univ of Washington
mi
from
Seattle, WA
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
Status: Enrolling
Updated: 4/11/2018
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  4/11/2018
Northwestern University
mi
from
Chicago, IL
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 4/11/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  4/11/2018
University of Chicago
mi
from
Chicago, IL
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 4/11/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  4/11/2018
Northwestern Lake Forest Hospital
mi
from
Lake Forest, IL
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 4/11/2018
Northwestern Lake Forest Hospital
mi
from
Lake Forest, IL
Click here to add this to my saved trials
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  4/11/2018
Edward Cancer Center
mi
from
Naperville, IL
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 4/11/2018
Edward Cancer Center
mi
from
Naperville, IL
Click here to add this to my saved trials
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  4/11/2018
Central Dupage Hospital
mi
from
Warrenville, IL
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 4/11/2018
Central Dupage Hospital
mi
from
Warrenville, IL
Click here to add this to my saved trials
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated:  4/18/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated: 4/18/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated:  4/18/2018
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated: 4/18/2018
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated:  4/18/2018
Research Medical Center - HCA Midwest
mi
from
Kansas City, MO
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Status: Enrolling
Updated: 4/18/2018
Research Medical Center - HCA Midwest
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
A Pilot Study Evaluating the Utility of 18F-DOPA PET for Radiotherapy Treatment Planning of Malignant Glioma Patients
Status: Enrolling
Updated:  4/20/2018
The Mayo Clinic
mi
from
Rochester, MN
A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
A Pilot Study Evaluating the Utility of 18F-DOPA PET for Radiotherapy Treatment Planning of Malignant Glioma Patients
Status: Enrolling
Updated: 4/20/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated:  4/23/2018
New York University
mi
from
New York, NY
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated: 4/23/2018
New York University
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated:  4/23/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated: 4/23/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated:  4/23/2018
Providence Cancer Center
mi
from
Portland, OR
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated: 4/23/2018
Providence Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated:  4/23/2018
Oregon Health and Sciences University
mi
from
Portland, OR
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated: 4/23/2018
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
Status: Enrolling
Updated:  4/25/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
Status: Enrolling
Updated: 4/25/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Status: Enrolling
Updated:  4/26/2018
Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital)
mi
from
Chicago, IL
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Status: Enrolling
Updated: 4/26/2018
Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital)
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Status: Enrolling
Updated:  4/26/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Status: Enrolling
Updated: 4/26/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
A Pilot Study of Bevacizumab-Based Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
Status: Enrolling
Updated:  5/1/2018
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
A Pilot Study of Bevacizumab-Based Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
Status: Enrolling
Updated: 5/1/2018
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
A Pilot Study of Bevacizumab-Based Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
Status: Enrolling
Updated:  5/1/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
A Pilot Study of Bevacizumab-Based Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
Status: Enrolling
Updated: 5/1/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  5/1/2018
UCSF Department of Neurosurgery
mi
from
San Francisco, CA
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 5/1/2018
UCSF Department of Neurosurgery
mi
from
San Francisco, CA
Click here to add this to my saved trials
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  5/1/2018
University of Miami
mi
from
Miami, FL
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 5/1/2018
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  5/1/2018
Northwestern University
mi
from
Chicago, IL
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 5/1/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  5/1/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 5/1/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  5/1/2018
Valley Hospital
mi
from
Paramus, NJ
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 5/1/2018
Valley Hospital
mi
from
Paramus, NJ
Click here to add this to my saved trials
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  5/1/2018
Northern Westchester Hospital
mi
from
Mount Kisco, NY
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 5/1/2018
Northern Westchester Hospital
mi
from
Mount Kisco, NY
Click here to add this to my saved trials
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  5/1/2018
Columbia University
mi
from
New York, NY
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 5/1/2018
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated:  5/1/2018
University of Oklahoma
mi
from
Oklahoma City, OK
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling
Updated: 5/1/2018
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials